Aldeyra Therapeutics, Inc. (ALDX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$0.65+0.68%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Aldeyra Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.098
Annual ending 2026-12-31
Revenue	—	1.25M
EPS	—	-0.34
Annual ending 2027-12-31
Revenue	—	8.4M
EPS	—	-0.278

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain stable executive and board leadership	A supporting condition in Aldeyra Therapeutics, Inc.'s published investment case. The stated target is no major unexpected leadership departures next 4 quarters.	Under Pressure	unexpected key executive or director departures	1 planned departure vs 0 unexpected Director Martin Joyce decided not to stand for re-election; Darlene Deptula-Hicks appointed to Audit Committee. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Management stated this priority in 2 disclosures in 2026. The company appointed Darlene Deptula-Hicks to the Board and Audit Committee Chair in June 2026 and announced the departure of director Martin J. Joyce in April 2026. These leadership changes indicate active management of governance to support company growth. Delivery assessment Oct 24, 2026
Reduce cash from operations loss toward negative $5.1M	Cash from operations loss improved by $8.1M.	Intact	cash from operations worse than -5.1 million USD next quarter	Cash from operations: $-4.589M FY2026-Q2; GAAP. Published target: cash from operations >= -5.1 million USD next quarter. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 6, 2026-4,589,422 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Management has emphasized capital discipline in 3 disclosures including 2026-Q1 and 2026-Q2. Despite ongoing net losses of $3.45M in 2026-Q1 and $5.45M in 2026-Q2, cash and equivalents stood at $45.1M as of June 30, 2026, supporting an operational runway extended into 2029. The trajectory shows continued losses but prudent cash management sustaining operations. Delivery assessment Oct 24, 2026
Reduce operating losses toward negative $3.5M per quarter	A primary condition in Aldeyra Therapeutics, Inc.'s published investment case. The stated target is operating income >= -3.5 million USD next quarter.	Intact	operating income worse than -3.5 million USD next quarter	Operating income: $-5.851M FY2026-Q2; GAAP. Published target: operating income >= -3.5 million USD next quarter. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 6, 2026-5,850,507 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: d7434edf-5898-47df-953e-ab1b36156a40. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Management has emphasized capital discipline in 3 disclosures including 2026-Q1 and 2026-Q2. Despite ongoing net losses of $3.45M in 2026-Q1 and $5.45M in 2026-Q2, cash and equivalents stood at $45.1M as of June 30, 2026, supporting an operational runway extended into 2029. The trajectory shows continued losses but prudent cash management sustaining operations. Delivery assessment Oct 24, 2026
Advance clinical development and regulatory approval	A primary condition in Aldeyra Therapeutics, Inc.'s published investment case. The stated target is progress clinical trials and address FDA feedback.	Under Pressure	no meaningful progress on clinical trials or regulatory feedback	3rd CRL received vs target of progress FDA issued a third CRL for reproxalap on March 16, 2026; company announced intent to appeal on September 29, 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 distinct disclosures including 2026-Q1 and 2026-09-29 press releases. Management plans to submit a Formal Dispute Resolution Request for reproxalap with an FDA meeting expected in Q4 2026 and anticipates initiating a Phase 3 trial for ADX-2191 in 2027. These regulatory and clinical development efforts are ongoing with clear timelines, indicating active pursuit of approvals and pipeline advancement. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$-0.20 → Unavailable · observed estimates

FY2027 revenueUnavailable

$0.02B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.20	$15,799,400	5 / 5
2026-07-25	$-0.20	$15,799,400	5 / 5
2026-07-26	$-0.20	$15,799,400	5 / 5
2026-07-27	$-0.20	$15,799,400	5 / 5
2026-07-28	$-0.20	$15,799,400	5 / 5
2026-07-29	$-0.20	$15,799,400	5 / 5
2026-07-30	$-0.20	$15,799,400	5 / 5
2026-07-31	Unavailable	Unavailable	4 / 4
2026-08-01	Unavailable	Unavailable	4 / 4
2026-08-02	Unavailable	Unavailable	4 / 4
2026-08-03	Unavailable	Unavailable	4 / 4
2026-08-04	Unavailable	Unavailable	4 / 4
2026-08-05	Unavailable	Unavailable	4 / 4
2026-08-06	Unavailable	Unavailable	4 / 4
2026-08-07	Unavailable	Unavailable	3 / 3
2026-08-08	Unavailable	Unavailable	4 / 4
2026-08-09	Unavailable	Unavailable	4 / 3
2026-08-10	Unavailable	Unavailable	4 / 3
2026-08-11	Unavailable	Unavailable	4 / 3
2026-08-12	Unavailable	Unavailable	4 / 3
2026-08-13	Unavailable	Unavailable	4 / 2
2026-08-14	Unavailable	Unavailable	3 / 3
2026-08-15	Unavailable	Unavailable	3 / 2
2026-08-16	Unavailable	Unavailable	3 / 2
2026-08-17	Unavailable	Unavailable	3 / 2
2026-08-18	Unavailable	Unavailable	3 / 3
2026-08-19	Unavailable	Unavailable	3 / 3
2026-08-20	Unavailable	Unavailable	3 / 3
2026-08-21	Unavailable	Unavailable	3 / 3
2026-08-22	Unavailable	Unavailable	3 / 3
2026-08-23	Unavailable	Unavailable	3 / 3
2026-08-24	Unavailable	Unavailable	3 / 3
2026-08-25	Unavailable	Unavailable	3 / 3
2026-08-26	Unavailable	Unavailable	3 / 3
2026-08-27	Unavailable	Unavailable	3 / 3
2026-08-28	Unavailable	Unavailable	3 / 3
2026-08-29	Unavailable	Unavailable	3 / 3
2026-08-30	Unavailable	Unavailable	3 / 3
2026-08-31	Unavailable	Unavailable	3 / 3
2026-09-01	Unavailable	Unavailable	3 / 3
2026-09-02	Unavailable	Unavailable	3 / 3
2026-09-03	Unavailable	Unavailable	3 / 3
2026-09-04	Unavailable	Unavailable	3 / 3
2026-09-05	Unavailable	Unavailable	3 / 3
2026-09-06	Unavailable	Unavailable	3 / 3
2026-09-07	Unavailable	Unavailable	3 / 3
2026-09-08	Unavailable	Unavailable	3 / 3
2026-09-09	Unavailable	Unavailable	3 / 3
2026-09-10	Unavailable	Unavailable	3 / 3
2026-09-11	Unavailable	Unavailable	3 / 3
2026-09-12	Unavailable	Unavailable	3 / 3
2026-09-13	Unavailable	Unavailable	3 / 3
2026-09-14	Unavailable	Unavailable	3 / 3
2026-09-15	Unavailable	Unavailable	3 / 3
2026-09-16	Unavailable	Unavailable	3 / 3
2026-09-17	Unavailable	Unavailable	3 / 3
2026-09-18	Unavailable	Unavailable	3 / 3
2026-09-19	Unavailable	Unavailable	3 / 3
2026-09-20	Unavailable	Unavailable	3 / 3
2026-09-21	Unavailable	Unavailable	3 / 3
2026-09-22	Unavailable	Unavailable	3 / 3
2026-09-23	Unavailable	Unavailable	3 / 3
2026-09-24	Unavailable	Unavailable	3 / 3
2026-09-25	Unavailable	Unavailable	3 / 3
2026-09-26	Unavailable	Unavailable	3 / 3
2026-09-27	Unavailable	Unavailable	3 / 3
2026-09-28	Unavailable	Unavailable	3 / 3
2026-09-29	Unavailable	Unavailable	3 / 3
2026-09-30	Unavailable	Unavailable	3 / 3
2026-10-01	Unavailable	Unavailable	3 / 3
2026-10-02	Unavailable	Unavailable	3 / 3
2026-10-03	Unavailable	Unavailable	3 / 3
2026-10-04	Unavailable	Unavailable	3 / 3
2026-10-05	Unavailable	Unavailable	3 / 3
2026-10-06	Unavailable	Unavailable	3 / 3
2026-10-07	Unavailable	Unavailable	3 / 3
2026-10-08	Unavailable	Unavailable	3 / 3
2026-10-09	Unavailable	Unavailable	3 / 3
2026-10-10	Unavailable	Unavailable	3 / 3
2026-10-11	Unavailable	Unavailable	3 / 3
2026-10-12	Unavailable	Unavailable	3 / 3
2026-10-13	Unavailable	Unavailable	3 / 3
2026-10-14	Unavailable	Unavailable	3 / 3
2026-10-15	Unavailable	Unavailable	3 / 3
2026-10-16	Unavailable	Unavailable	3 / 3
2026-10-17	Unavailable	Unavailable	3 / 3
2026-10-18	Unavailable	Unavailable	3 / 3
2026-10-19	Unavailable	Unavailable	3 / 3
2026-10-20	Unavailable	Unavailable	3 / 3
2026-10-21	Unavailable	Unavailable	3 / 3
2026-10-22	Unavailable	Unavailable	3 / 3
2026-10-23	Unavailable	Unavailable	3 / 3
2026-10-24	Unavailable	Unavailable	3 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	5	1
2026-06-01	4	1
2026-07-01	5	1
2026-08-01	5	1
2026-09-01	5	1
2026-10-01	5	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain stable executive and board leadershipPublished status: Under Pressure
Reduce cash from operations loss toward negative $5.1MCash from operations: $-4.589M
Reduce operating losses toward negative $3.5M per quarterOperating income: $-5.851M
Advance clinical development and regulatory approvalPublished status: Under Pressure

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.9%Typical daily move · historical

Downside history

-88.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Aldeyra Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative, loss-making biotechnology company whose longer-term prospects depend on clinical development and regulatory approval. The thesis is described as intact, but confidence is low and risk is high.

What's priced into Aldeyra Therapeutics, Inc.

The evidence does not provide a valuation measure or specific market expectations, so whether ALDX is cheap or expensive versus peers cannot be assessed. The recent FDA rejection is a negative event, while the evidence says the recent price reaction was down and the thesis reason remains intact.

What the fundamentals likely do

Near term, ongoing losses and an elevated risk of a next-quarter earnings miss remain important concerns. Management plans to seek an FDA meeting about reproxalap in Q4 2026 and anticipates starting a Phase 3 trial for ADX-2191 in 2027; cash of $45.1 million as of June 30, 2026 was reported to support operations into 2029. Sector conditions have improved, but the evidence on recent financial performance is neutral.

What Aldeyra Therapeutics, Inc. hinges on

The multi-year thesis hinges on regulatory progress for reproxalap, advancement of ADX-2191, and management maintaining capital discipline while losses continue. Near-term sector support could persist if major healthcare companies keep beating earnings and guiding higher, but weaker jobs data or disappointing results from those companies could weaken that backdrop.